Technology News and Research

RSS

Phadia's ImmunoCAP Rapid System receives FDA marketing clearance

Phadia, the world leader in allergy blood testing diagnostics, today announced that the United States Food and Drug Administration (FDA) has cleared the ImmunoCAP® Rapid Reader II, a part of the ImmunoCAP Rapid System, used to aid in the diagnosis of allergy in the physician’s office.

27 Jan 2010

Radiation therapy safe and effective for cancer treatment

In response to the issues raised by the Jan. 24 New York Times article, "Radiation Offers New Cures and Ways to Do Harm," US Oncology, Inc. wants to ensure that cancer patients and the general public understand that the benefits received from radiation therapy in cancer care far outweigh the risks, and that cancer patients fighting their disease with help from the US Oncology physician network, and their loved ones, can rest assured that extensive quality control measures are put in place to minimize risks.

27 Jan 2010

Applied Biosystems signs cross-licensing agreement with Idaho Technology

Applied Biosystems LLC, part of Life Technologies Corporation, and Idaho Technology, Inc. have signed a cross-licensing agreement which covers a broad range of products including hardware, software and reagents.

27 Jan 2010

Health IT money secured, but program faces challenges

Washington has channeled billions of dollars to help hospitals and doctors adopt electronic medical records, but obstacles remain on the horizon. One possible challenge is that no entity has yet been named to "test and certify" the records, Modern Healthcare reports. Nonetheless, one group, The Certification Commission for Health Information Technology, will begin taking applications Feb. 12 from health IT vendors to do just that. The group fulfilled the certifying function for much of the Bush administration and gained the confidence of then-HHS Secretary Michael Leavitt.

27 Jan 2010

BioElectronics signs contract with YesDTC Holdings to enter the Japanese market

BioElectronics Corp., the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the signing of a contract with YesDTC Holdings, Inc. (YESD.OB) to enter the Japanese market and receipt of the single largest product order and revenue commitment in company history.

26 Jan 2010

First commercial implants of ATS Medical's ATS 3f Enable Aortic Bioprosthesis performed

ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced the first commercial implants of the ATS 3f Enable® Aortic Bioprosthesis were recently performed at the University of Berne Hospital, Berne, Switzerland by Lars Englberger, MD, Mario Stalder, MD, and Professor Thierry Carrel. The procedures were completed using a sutureless technique and the patients are recovering with no complications.

25 Jan 2010

Sagefrog Marketing Group awarded a contract for Agency of Record

Penn Pharma Americas announced today that Sagefrog Marketing Group, LLC, a full service marketing, interactive and public relations company, has been awarded a contract for Agency of Record for both marketing and public relations.

25 Jan 2010

Acacia Research subsidiary acquires rights to intraluminal device technology patent

Acacia Research Corporation announced today that a subsidiary has acquired the rights to a patent for intraluminal device technology.

25 Jan 2010

IntelGenx and LTS announce strategic alliance

IntelGenx Corp. ("IntelGenx") today announced a strategic alliance with LTS Lohmann Therapie-Systeme AG ("LTS") for the exclusive manufacturing of products developed by IntelGenx using its VersaFilm drug delivery technology.

25 Jan 2010

NTNU: 40% of two-year-olds report allergy-related disorders

Allergies and asthma are a continuing health problem in most developed countries, but just how do these ailments develop over the course of a childhood? In a population-based study designed to help answer this question, researchers at the Norwegian University of Science and Technology (NTNU) found that 40 per cent - or two of five -- of nearly 5,000 two-year-olds had at least one reported allergy-related disorder. The most common symptom was wheezing, which was reported in 26 per cent of all children in the study, says Ingeborg Smidesang, a PhD candidate in the university's Faculty of Medicine, and the primary author of the study.

25 Jan 2010

IntegraGen now offers Fluidigm's IFC technology to French researchers

Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France’s leading providers of genetic research testing services, to bring IFC technology to French researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen’s lab will also be a demonstration site for researchers investigating Fluidigm’s technology.

25 Jan 2010

Halozyme Therapeutics and BioAtla sign research collaboration agreement

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation.

25 Jan 2010

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient was dosed in a registrational, open-label, multicenter trial designed to evaluate the safety, pharmacokinetics and efficacy of the companies’ long-acting, recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients.

25 Jan 2010

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS).

25 Jan 2010

Dr. Reddy's gains access to Aegis' Intravail drug delivery technology for undisclosed therapeutics

Dr. Reddy's Laboratories (NYSE: RDY) and Aegis Therapeutics, LLC (Aegis) today announced a partnership providing Dr. Reddy's access to Aegis' Intravail® drug delivery technology for certain undisclosed therapeutics currently being marketed with annual worldwide sales in excess of U.S. $1 billion. Financial terms were not disclosed.

25 Jan 2010

Welch Allyn to showcase next-generation electronic connectivity technology at 2010 Arab Health Congress in Dubai

Welch Allyn, a leading global manufacturer of frontline medical products and solutions, will showcase its newest suite of core diagnostics product offerings that feature next-generation electronic connectivity technology this week at the 2010 Arab Health Congress in Dubai, U.A.E.

24 Jan 2010

Technology News and Research

Phadia's ImmunoCAP Rapid System receives FDA marketing clearance

Radiation therapy safe and effective for cancer treatment

Applied Biosystems signs cross-licensing agreement with Idaho Technology

Health IT money secured, but program faces challenges

BioElectronics signs contract with YesDTC Holdings to enter the Japanese market

First commercial implants of ATS Medical's ATS 3f Enable Aortic Bioprosthesis performed

Sagefrog Marketing Group awarded a contract for Agency of Record

Acacia Research subsidiary acquires rights to intraluminal device technology patent

IntelGenx and LTS announce strategic alliance

NTNU: 40% of two-year-olds report allergy-related disorders

IntegraGen now offers Fluidigm's IFC technology to French researchers

Halozyme Therapeutics and BioAtla sign research collaboration agreement

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Dr. Reddy's gains access to Aegis' Intravail drug delivery technology for undisclosed therapeutics

Welch Allyn to showcase next-generation electronic connectivity technology at 2010 Arab Health Congress in Dubai

OrbusNeich's clinical data demonstrates the benefits of Genous Bio-engineered R stent

Loss of key proteins may account for molecular abnormalities associated with myotonic dystrophy

New technology may allow scientists to monitor real time activity of protein network

Pro-Dex' customer abandons commercialization of new battery-powered shaver system

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News